Variation in QRISK2 score recording and statin prescribing according to demographic group from clinical encounters relating to CVD in 2012–2015
| Characteristic | QRISK2 score, no statin, n (%) | QRISK2 score, subsequent statin, n (%) | Statin initiated without QRISK2, n (%) | Proportion of initiations without QRISKa | |
|---|---|---|---|---|---|
| Sex | Male | 54 874 (67.5) | 7134 (8.8) | 19 281 (23.7) | 0.73 |
| Female | 79 438 (76.3) | 6691 (6.4) | 17 934 (17.2) | 0.73 | |
| Age group, years | 40–49 | 42 913 (84.7) | 1347 (2.7) | 6396 (12.6) | 0.83 |
| 50–59 | 43 924 (75.6) | 3255 (5.6) | 10 943 (18.8) | 0.77 | |
| 60–69 | 33 007 (65.0) | 5542 (10.9) | 12 201 (24.0) | 0.69 | |
| ≥70 | 11 468 (50.2) | 3681 (16.1) | 7675 (33.6) | 0.68 | |
| Townsend deprivation quintile | 1st | 40 004 (74.4) | 3669 (6.8) | 10 080 (18.8) | 0.73 |
| 2nd | 31 760 (73.4) | 3425 (7.9) | 8087 (18.7) | 0.70 | |
| 3rd | 27 546 (72.0) | 2896 (7.6) | 7804 (20.4) | 0.73 | |
| 4th | 19 185 (68.2) | 2272 (8.1) | 6654 (23.7) | 0.75 | |
| 5th | 10 829 (66.5) | 1380 (8.5) | 4072 (25.0) | 0.75 | |
| Missing | 4988 (87.7) | 183 (3.2) | 518 (9.1) | 0.74 | |
| Total | 134 312 (72.5) | 13 825 (7.5) | 37 215 (20.1) | 0.73 | |
↵a Proportions in bold show significant trend (P<0.001) by Pearson’s χ2 test.